Dossier assessment
Evinacumab (homozygous familial hypercholesterolaemia; adults and adolescents >= 12 years) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Evinacumab (homozygous familial hypercholesterolaemia; adults and adolescents >= 12 years) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Evinacumab (homozygous familial hypercholesterolaemia; adults and adolescents >= 12 years) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adults and adolescents aged 12 years and older with homozygous familial hypercholesterolaemia in whom dietary and drug options for lipid lowering have been exhausted
Added benefit not proven
Project details
- Project no.
- A24-05
- Commission
- Commission awarded on 10.01.2024 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Digestion, metabolism and hormones
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
https://doi.org/10.60584/A24-05_en
Connected Projects
-
Dossier assessment
Evinacumab (homozygous familial hypercholesterolaemia, 5 to 11 years) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed